| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at two upcoming scientific meetings: the American Society of Consultant Pharmacists (ASCP) Annual Meeting (October 23–25, 2025) and the Neuroscience Education Institute (NEI) Annual Congress (November 6–9, 2025).The Company's accepted poster presentations include:
ASCP Annual Meeting
NEI Annual Congress
It has been more than a decade since the last cholinesterase inhibitor came off patent, and during that time, these agents have faded from clinical focus," said Dr. Denis Kay, Chief Scientific Officer at Alpha Cognition. "It is important to reintroduce the well-established role of these medications in the treatment of Alzheimer's disease (AD). Unless contraindicated, most AD patients should receive these treatments as first-line therapy. The recent introduction of the enteric-coated prodrug ZUNVEYL (benzgalantamine) provides cholinesterase inhibition and nicotinic acetylcholine receptor modulation in a novel formulation designed to address prior challenges in treatment continuity."
Posted In: ACOG
